Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More cuts at Novoste

This article was originally published in The Gray Sheet

Executive Summary

Termination of 86 employees, announced March 31, is attributed to the impact of drug-eluting stents on the company's core business opportunity in brachytherapy treatment of in-stent restenosis. The move will save over $6 mil. annually and cost about $716,000 in severance, according to the Norcross, Ga. firm. The 40% workforce cut comes 13 months after the company laid off 35 people to save $3 mil. annually. However, the firm's sales force remains intact, in keeping with a 2002 plan to withstand expected DES-related loss of business in 2003 and 2004 (1"The Gray Sheet" Jan. 21, 2002, p. 12)...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts